body aches on glp 1 Do associated with Glucagon-like peptide-1 (GLP-1) receptor agonists subside? Stories like this are why

Description

[DOI] [PubMed] [Google Scholar] 43.Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

I love peptides

Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods

In rodents with 6-OHDA and ROT-induced lesions, GLP-1R was associated with increased expression of B-cell lymphoma-2 (Bcl-2) and complex I and reduced expression of caspase-3, halting cell death [82,83]

When to seek medical advice : Patients should contact their GP or prescribing clinician if nausea is severe and persistent, if they are unable to keep down fluids for more than 24 hours, if they experience severe abdominal pain, or if side effects significantly impact their quality of life